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Background: Studies suggest that the 9p21-3 locus may influence susceptibility to myocardial infarction. We performed
a systematic review and meta-analysis to assess whether this locus is associated with severity of coronary atherosclerosis
and adverse clinical outcomes in those with known coronary disease.
Methods: Multiple electronic databases were searched from inception through August 2012. Studies examining 9p21-3
genotype in patients with known coronary artery disease were included. We extracted the association of the 9p21-3
locus with measures of severity of coronary atherosclerosis [number of diseased vessels, Gensini Score, Duke CAD
Prognostic Index (DPI)], angiographic outcomes [change in minimum lumen diameter (ΔMLD) and number of
new lesions at follow-up], and key clinical outcomes (all-cause mortality, recurrent myocardial infarction and the
need for coronary revascularization). Relative risks (RR) and weighted mean difference (WMD) were pooled using
the random effects models.
Results: 23 cohorts enrolling 16,860 participants were analyzed. There was no significant difference between HR
and LR genotypes in terms of all-cause mortality, recurrent myocardial infarction or the frequency of coronary
revascularization. HR genotype was associated with increased risk of triple vessel disease (RR = 1.34; 95% CI 1.08-1.65;
P = 0.01) and increased baseline Gensini Score (WMD = 5.30; 95% CI 0.66-9.93; P = 0.03). However there was no
association with DPI (WMD = 4.00; 95% CI 2.94-10.94; P = 0.26). HR genotype did not predict ΔMLD or number
of new lesions at follow-up.
Conclusions: Patients of coronary atherosclerosis who carry the high risk genotype of the 9p21-3 allele may
be more likely to have multi-vessel CAD. However the effect of this allele on CAD progression and disease
specific clinical outcomes are not observed possibly due to diminishing genetic risk following dietary modification
and therapy.
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Coronary artery disease (CAD) remains a worldwide lead-
ing cause of mortality. Modification of major environmen-
tal risks such as smoking and high cholesterol reduces
CAD mortality by 20% to 30% [1]. The presence of a posi-
tive family history as a strong risk factor in CAD points to
underlying genetic risk factors [2].* Correspondence: Wang.Zhen@mayo.edu
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unless otherwise stated.Genome wide association studies (GWAS) have identi-
fied over 30 risk variants for CAD [3,4]. Of these, the
variant on the p arm of chromosome 9 at position 21–3
(9p21-3) is the most well-known and replicated. Many
studies have established and replicated the association of
the 9p21-3 locus with CAD and myocardial infarction
(MI). Other studies have revealed that targeted deletion
of the 9p21 non-coding interval leads to excessive prolif-
eration of vascular smooth muscle cells as well as their
diminished senescence [5]. Some 9p21 variants alsotd. This is an Open Access article distributed under the terms of the Creative
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which might explain some of the genetic susceptibility
underpinning CAD [6]. Variants at this locus have also
been associated with a lower ankle-brachial index (ABI),
which is a marker of increased risk for death and incident
cardiovascular disease (CVD) events [7]. The effect of the
9p21-3 locus on angiographic severity and clinical out-
comes in patients with established CAD has been tested
by several investigators. However, findings from these re-
ports are conflicting.
We therefore conducted a systematic review and meta-
analysis of the published literature investigating the associ-
ation of the 9p21-3 locus with angiographic CAD severity,
progression, and key clinical outcomes.
Methods
The reporting of this systematic review complies with
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement [8].
Eligible studies were comparative studies of human
subjects, provided genotyping was done at the 9p21-3
locus in a population with known coronary artery dis-
ease (previous/recent MI, or known epicardial coronary
stenosis at enrollment). Applicable study designs in-
cluded observational studies (case–control, cohort and
cross sectional) where an association between the 9p21-
3 allele and poor outcome or prognostic marker was re-
ported. Only studies written in English were included
due to feasibility.
We searched Ovid MEDLINE from 1948 until August
2012 and Ovid EMBASE, Web of Science and SCOPUS,
from inception to August 2012. Subject headings (MeSH,
EMTREE) were used: Chromosomes, Pair 9, Coronary ar-
tery disease, alleles and atherosclerosis. Keywords (9p21*)
were used in Web of Science and Scopus. The detailed
search strategy is attached in Additional file 1.
A team of two trained reviewers independently screened
all articles identified in the literature search. Discrepancies
between the reviewers were resolved through discussions
and consensus.
Markers of atherosclerotic severity included number of
diseased vessels, Gensini Score and Duke CAD Prognostic
Index (DPI). Markers of atherosclerotic severity and coron-
ary disease progression are defined elsewhere [9]. We also
assessed change in minimum lumen diameter (ΔMLD)
and number of new lesions at follow-up. Outcomes of
interest included all-cause mortality, recurrent MI, need
for coronary revascularization, triple vessel disease, Gensini
score, DPI, ΔMLD, and number of new lesions. In studies
where all-cause and cause-specific mortalities were separ-
ately tested, we analyzed all-cause mortality only.
Recurrent MI was defined any acute coronary syn-
drome associated with troponin elevation and/or ST seg-
ment elevation on electrocardiography (ECG). Need forcoronary re-vascularization included surgical and percu-
taneous procedures performed either at target or non-
target coronary vessels.
We extracted details on sample size, mean age, race, the
identification (rs number) of the particular SNP geno-
typed, and outcomes of interest. SNPs previously reported
in GWAS studies or in strong linkage disequilibrium with
them were considered in the analysis.
In keeping with our goal to determine locus-outcome as-
sociation we did not limit our analysis to a single SNP but
instead tested for all available SNPs published in reports
chosen for the meta-analysis. In studies reporting > 1 SNP-
outcome association, we chose the SNP not elsewhere tested
in other data sets. This allows us to capture all known
markers in the locus and test as many markers as possible.
We used the Newcastle-Ottawa Quality Assessment to
assess the risk of bias of the included studies [10]. The
following items were used: selection of patients, compar-
ability, assessment of exposure and/or outcome, length
of follow-up, lost to follow-up. We were unable to assess
potential publication bias due to limited number of stud-
ies included for each outcome [11].
Genotypes were classified as either homozygous low risk
(LR) heterozygous intermediate risk (IR) or homozygous
high risk (HR). Study results were variedly reported using
recessive [LR vs. (IR +HR)], dominant [(LR + IR) vs. HR)]
and additive models [LR vs. IR vs. HR]. For the purpose of
this manuscript we included additive models. For dichoto-
mized outcomes, we extracted or calculated relative risk
(RR) and its 95% confidence intervals (CI). We then pooled
RR across the studies using the DerSimonian and Laird
random effects methods with the heterogeneity from the
Mantel–Haenszel method [12]. For continuous outcomes,
we pooled weighted mean difference (WMD) using the
same DerSimonian and Laird random effects methods.
We assessed the optimal information size (OIS), simi-
lar to power calculation in clinical trials, to evaluate the
minimum sample size required in the literature to reach
reliable conclusions [8].
We assessed the consistency of the outcomes by testing
heterogeneity using the I2 statistic, where I2 > 50% sug-
gests a high level of heterogeneity [13]. All statistical ana-
lyses were conducted using STATA version 12 (StataCorp,
College Station, TX).
Results
The literature search yielded 229 studies of which 21
(describing 23 distinct cohorts) met criteria for inclu-
sion. Study selection process is described in (Figure 1).
Table 1 lists the studies entered in the meta-analysis to-
gether with outcomes tested in each study.
The methodological quality of the included studies
was fair, with the majority of them providing ad-
equate representativeness of study patients, comparability
PRISMA 2009 Flow Diagram 
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Figure 1 Flow Chart: PRISMA 2009 Flow Diagram.
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posure and/or outcome (Figure 2). Also, in all of the out-
comes, except all-cause mortality, triple vessel disease, and
Gensini Score, the total sample size reported in the studies
were less than the OIS. We, thus, were unable to reach
conclusive findings for these outcomes.
We did not find a significant association between 9p21-3
and all-cause mortality (RR = 1.11; 95% CI 0.88-1.40;
p = 0.39, I2 = 51.6%) (Figure 3).
Likewise, no significant association emerged in the
meta-analysis of 9p21-3 with recurrent MI in patients
with known CAD in the additive model (RR = 1.14; 95%
CI 0.92-1.40; p = 0.24; I2 = 7.0%). Table 2 lists the sum-
mary statistics for the outcomes.
Four cohorts from 3 studies reported need for re-
vascularization. No significant association was identified
between 9p21-3 and re-vascularization after development
of CAD (RR = 1.11; 95% CI 0.78-1.57; p = 0.56; I2 = 78.1%).
The meta-analysis supported an association between
9p21-3 and triple vessel disease. Homozygotes (HR) for
the risk allele had significantly greater risk (RR = 1.34,
95% CI 1.08-1.65, p = 0.01, I2 = 53.8%).Three studies reported severity of CAD as measured by
Gensini score at baseline. Combined analysis of these
studies showed 5.30 higher mean Gensini score in the LR
group vs. the HR group. This difference was significant
(95% CI 0.66-9.93; p = 0.03; I2 = 80.2%). However the DPI
which also quantifies CAD severity was not significant in
the combined analysis of the two studies reporting it
(WMD= 4.00; 95% CI −2.94-10.94; p = 0.26; I2 = 87.5%).
Combined analysis of two studies testing for association
of angiographic progression as measured by Δ MLD and
number of new lesions at follow-up revealed no associ-
ation with the 9p21-3 allele. The combined WMD for Δ
MLD was 0.07 (95% CI −0.02-0.15; p = 0.15; I2 = 1.0%)
and new lesions at follow up was 0.03 (95% CI −0.05-0.10;
p = 0.49; I2 = 0.0%).
Discussion
In this meta-analysis of studies investigating angio-
graphic severity and clinical outcomes in patients with
CAD, we found an association of 9p21-3 allele with in-
creased risk of triple vessel disease and greater quantita-
tive severity of atherosclerosis as measured with the
Table 1 Characteristics of the included studies
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Figure 2 Risk of bias of the included studies.
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http://www.biomedcentral.com/1471-2350/15/66Gensini score at baseline. The meta-analysis did not sup-
port an association of the allele with angiographic out-
comes at follow up or clinical outcomes.
Our findings are consistent with the results of Chan
et al. [35] who reported a 23% greater risk of triple vesselFigure 3 Pooled relative risk of all cause mortality using additive [LR
(IR + HR)] models.disease among high risk homozygotes when compared
with their low risk genetic counterparts. Different from
Chan’s study, we analyzed more outcomes, including
measures of severity of coronary atherosclerosis [number
of diseased vessels, Gensini Score, Duke CAD Prognosticvs. IR vs. HR], dominant [(LR + IR) vs. HR)], and recessive [LR vs.
Table 2 Pooled statistics using additive [LR vs. IR vs. HR], dominant [(LR + IR) vs. HR)], and recessive [LR vs. (IR + HR)]
models
Number of cohorts Number of patients RR 95% CI P value I2
Recurrent MI 6 5795 1.14 0.92 1.40 0.24 7.0%
Revascularization 4 5225 1.11 0.78 1.57 0.56 78.1%
Triple vessel disease 4 1928 1.34 1.08 1.65 0.01 53.8%
WMD 95% CI p.value I2
Gensini Score 3 1470 5.30 0.66 9.93 0.03 80.2%
DPI 2 1201 4.00 −2.94 10.94 0.26 87.5%
ΔMLD 2 293 0.07 −0.02 0.15 0.15 1.0%
No. new lesions 2 293 0.03 −0.05 0.10 0.49 0.0%
MI indicates myocardial infarction; DPI, Duke CAD prognostic index; ΔMLD, change in minimum lumen diameter; No. new lesions, number of new lesions.
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http://www.biomedcentral.com/1471-2350/15/66Index (DPI)], angiographic outcomes [change in mini-
mum lumen diameter (ΔMLD) and number of new le-
sions at follow-up], and key clinical outcomes (all-cause
mortality, recurrent myocardial infarction and the need
for coronary revascularization). We have for the first
time confirmed an association of the allele with a higher
Gensini score in a meta-analysis. In quantitative angiog-
raphy Gensini score is derived by assigning a severity
score to each coronary stenosis according to the degree
of luminal narrowing and its geographic importance
[28]. The score correlates positively with number of ves-
sel segments involved. Thus it is intuitive that an associ-
ation of 9p21-3 allele with triple vessel disease would
translate into an association with the Gensini score in
the same direction. However the lack of association with
the DPI was surprising. A positive linear correlation be-
tween the Gensini and the DPI score is reported in the
literature [9]. It is possible that the analysis of DPI was
underpowered due to fewer studies reporting this associ-
ation compared to those reporting the Gensini score.
We found no association between the 9p21-3 allele
and angiographic outcomes. This was also unexpected
as the process underlying de-novo atherogenesis would
remain unchanged over the course of time. One likely
explanation can be index event bias [36]. Conceivably,
the risk factors distribution among patients with high
genetic risk may have shifted after diagnosis and subse-
quent lifestyle modification and initiation of therapy.
We found no association between genotypic risk and
all-cause mortality among CAD patients. This negative
finding is supportive of existing evidence published by
Ganna et al. [37] which showed that increased risk of
all-cause mortality was associated with polygenic risk
factors dispersed across the genome. In a sample of over
16,000 participants, a genome wide risk score derived
from 707 published SNPs was associated with a modest
10% increased hazard of death. In our study we tested
for association between a single locus in a smaller sam-
ple which could have further lowered the likelihood of
finding an association.Most GWAS showing locus-disease association, have
shown positive results in conditions which are observed
to be heritable. Given that there is no published study
reporting heritability of the risk of re-infarction, the gen-
etic risk of recurrent events among survivors of ACS re-
mains less probable; an observation noted in our meta-
analysis. Likewise in the case of TLR, which could result
either from progression of atherosclerosis or recurrent
acute ischemic events, we anticipated no association
given the absence of increased risk of disease progres-
sion and re-infarction among 9p21-3 carriers.
Our study suffers some important limitations. First, we
cannot rule out that our findings may be due to chance
as multiple testing had been conducted. However, there
is no consensus when this problem should be taken into
account and which statistical method should be used in
meta-analysis [38,39]. Second, the sample size in most of
the outcomes reported in the studies was less than the
OIS. Thus, we may not have the power to detect weaker
associations. At last, our analyses restricted to associ-
ation studies as no linkage analyses have identified this
allele to be associated with CAD.Conclusion
Patients of CAD who carry the high risk genotype of the
9p21-3 allele may be more likely to have multi-vessel
CAD. However the effect of this allele on CAD progres-
sion and disease specific clinical outcomes are not ob-
served possibly due to diminishing genetic risk following
dietary modification and therapy.Additional file
Additional file 1: Search Strategy.
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